FBIO earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E 0.92. Updated 2026-07-23.
Fortress Biotech (FBIO) Research Hub
Fortress Biotech (FBIO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.52 USD (-4.18%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 0.92, market cap 0.12B. This hub links to the full technical, earnings and options research available for FBIO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.52 USD (-4.18%) |
| 52-week range | 2.52 USD – 3.84 USD |
| Trend regime | Range |
| 14-day RSI | 43 (Bearish) |
| Trailing P/E | 0.92 |
| Market cap | 0.12B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for FBIO
Covered Call on FBIO: how it works, illustrative setup around the real 2.52 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on FBIO: how it works, illustrative setup around the real 2.52 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on FBIO: how it works, illustrative setup around the real 2.52 USD price, max profit/loss, breakeven and when to use it. Educational.
FBIO technical analysis: range, last 2.52 USD, RSI 43, 52w range 2.52 USD–3.84 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is FBIO in?
Fortress Biotech (FBIO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is FBIO in an uptrend or downtrend?
As of 2026-09-11, FBIO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is FBIO's trailing P/E ratio?
FBIO's trailing P/E is 0.92, with a market cap of 0.12B. See the earnings research page for full valuation detail.
When does FBIO next report earnings?
FBIO is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.2 USD.